Values First Advisors
ALNY icon

Values First Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Values First Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$770K Sell
3,121
-57
-2% -$14.5K 0.36% 77
2026
Q2 		$957K Sell
3,178
-68
-2% -$20.5K 0.44% 67
2026
Q1 		$1.07M Buy
3,246
+20
+0.6% +$6.81K 0.56% 55
2025
Q4 		$1.28M Sell
3,226
-656
-17% -$290K 0.67% 48
2025
Q3 		$1.77M Sell
3,882
-65
-2% -$26.5K 0.95% 40
2025
Q2 		$1.29M Sell
3,947
-4,166
-51% -$1.15M 0.7% 48
2025
Q1 		$2.19M Sell
8,113
-879
-10% -$226K 1.28% 16
2024
Q4 		$2.12M Buy
8,992
+202
+2% +$53.1K 1.16% 17
2024
Q3 		$2.42M Buy
8,790
+1,200
+16% +$312K 1.31% 15
2024
Q2 		$1.84M Sell
7,590
-148
-2% -$23.4K 1.11% 31
2024
Q1 		$1.16M Buy
7,738
+755
+11% +$126K 0.68% 45
2023
Q4 		$1.34M Buy
6,983
+476
+7% +$81.1K 0.81% 41
2023
Q3 		$1.15M Sell
6,507
-50
-0.8% -$9.5K 0.74% 42
2023
Q2 		$1.25M Buy
6,557
+146
+2% +$28.9K 0.75% 42
2023
Q1 		$1.28M Buy
6,411
+109
+2% +$22.9K 0.82% 35
2022
Q4 		$1.5M Buy
6,302
+35
+0.6% +$7.46K 1.05% 30
2022
Q3 		$1.25M Buy
6,267
+201
+3% +$38.3K 0.9% 35
2022
Q2 		$885K Sell
6,066
-430
-7% -$61K 0.63% 52
2022
Q1 		$1.06M Buy
6,496
+347
+6% +$52.9K 0.67% 49
2021
Q4 		$1.04M Sell
6,149
-368
-6% -$68.4K 0.62% 56
2021
Q3 		$1.23M Buy
6,517
+213
+3% +$40K 0.8% 43
2021
Q2 		$1.07M Sell
6,304
-130
-2% -$19K 0.73% 49
2021
Q1 		$908K Buy
6,434
+99
+2% +$14.9K 0.67% 52
2020
Q4 		$823K Sell
6,335
-199
-3% -$26.6K 0.66% 54
2020
Q3 		$951K Buy
6,534
+331
+5% +$47K 0.87% 45
2020
Q2 		$919K Sell
6,203
-146
-2% -$19.7K 0.91% 45
2020
Q1 		$691K Buy
6,349
+367
+6% +$42.4K 0.83% 45
2019
Q4 		$689K Buy
+5,982
New +$596K 0.67% 54

Other funds holding ALNY

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Asset Management One
Asset Management One Tokyo, Japan $40B AUM 30.45% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
IFM Investors
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return
GF Fund Management
GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return
Virginia Retirement Systems
Virginia Retirement Systems Richmond, Virginia $16.3B AUM 35.33% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Values First Advisors's ALNY Position: Q3 2026 in Review

Values First Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 1.8% in Q3 2026, selling an estimated $14.5K and leaving 3,121 shares worth $770K. The position accounts for 0.36% of the portfolio, ranked #77.

Values First Advisors first reported a position in ALNY in Q4 2019 and has held it in 28 quarters since. The position peaked at $2.42M in Q3 2024. 174 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Values First Advisors held 3,121 shares of Alnylam Pharmaceuticals worth $770K as of Q3 2026.
  • Values First Advisors sold 57 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $14.5K.
  • Alnylam Pharmaceuticals made up 0.36% of Values First Advisors's portfolio in Q3 2026, its #77 holding.
  • Values First Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2019 and has held it in 28 quarters since.
  • Values First Advisors's Alnylam Pharmaceuticals position peaked at $2.42M in Q3 2024.
  • 174 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Values First Advisors's 13F filing for Q3 2026, filed 23 Oct 2026.